Dec 20, 2023

Featuring an interview with Dr David M O’Malley, including the following topics:

• Prevalence of HER2 positivity among various gynecologic cancer subtypes; current testing recommendations (0:00)
• Trastuzumab and other HER2-targeted therapies as a component of treatment for HER2-positive gynecologic cancers (15:17)
• Key efficacy outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study (18:05)
• Incidence of interstitial lung disease (ILD) and other toxicities with T-DXd in the DESTINY-PanTumor02 trial; strategies to manage ILD associated with HER2-directed antibody-drug conjugates (27:59)
• Case: A woman in her mid-60s with HER2-low (IHC 1+) recurrent uterine carcinosarcoma receives T-DXd on a clinical trial (34:26)
• Case: A woman in her mid-70s with recurrent uterine serous cancer and history of Crohn’s disease (51:05)
• Case: A woman in her mid-60s with Stage IIIC primary uterine serous cancer receives carboplatin/paclitaxel/trastuzumab followed by maintenance trastuzumab with no evidence of disease 4 years later (56:50)

CME information and select publications